SSI Diagnostica Holding A/S

Central Business Registration no. 37 39 77 76

Herredsvejen 2 3400 Hillerød Denmark



Annual Report and consolidated Financial Statements

1 January – 31 December 2022

The Annual Report was presented and adopted at The Annual General Meeting of The Company on 30 May 2023

Marie Holst Chair of the meeting

Contents

| Company details | 1 |
|--|----|
| Company Group Chart | 2 |
| Management review 2022 | 3 |
| Financial Highlights | 8 |
| Statement by management on the annual report | 9 |
| Independent auditor's report | 10 |
| Accounting policies | 13 |
| Income statement 1 January – 31 December 2022 | 23 |
| Balance sheet at 31 December 2022 | 24 |
| Statement of change in equity 31 December 2022 | 27 |
| Cash flow statement 1 January – 31 December 2022 | 28 |
| Notes | 29 |

Company details

The Company

SSI Diagnostica Holding A/S Herredsvejen 2 3400 Hillerød Denmark

Central Business Registration no. 37 39 77 76 Financia period: 1 January – 31 December 7th financial year

Executive Board

Christina Charlotte Lindved Egil Mølsted Madsen Søren Skjold Mogensen


Supervisory Board

Stig Løkke Pedersen (Chairman) Steffen Kjeld Thomsen Patrick Olof Dahlén Rasmus Karl Gustaf Molander Catherine Yaping Chen Sibel Karina Arnes

Company Auditors

PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab Strandvejen 44 2900 Hellerup Central Business registration no. 33 77 12 31

Company Group Chart



Management review 2022

Primary activities

The Group develops, produces, and sells in vitro diagnostic products mainly within clinical microbiology, as well as products to the vaccine industry, veterinary diagnostics as well as products within food, environmental, hygiene and quality control.

SSI Diagnostica Holding A/S primary activity is ownership of companies decided by the board.

Segments

The company's activities are divided into the following segments.

Disease Prevention

The category Disease Prevention includes antisera, antigens and other in vitro diagnostics (IVD) products to be used for quality testing of vaccines and typing of bacteria such as E. coli, pneumococci, salmonella and streptococci.

Rapid Screening

Rapid Screening relates to rapid tests for the qualitative detection of bacteria and vira including COVID-19 tests, tests for dengue fever tropical diseases.

The category also includes ImmuView, a category of rapid tests that includes ImmuView Reader, a portable test instrument providing automatic and quick analysis of tests when testing for pneumoniae, legionella etc.

With the acquisition of TechLab, SSI Group has achieved a strong position in USA and broadened the category of rapid screenings products within enteric diagnostics. TechLab's tests within Rapid Screening include tests for intestinal C. difficile, inflammation and parasitology. The company produces a panel of in vitro diagnostics for detecting C. difficile and its toxins in specimens from patients suspected of having the disease.

MI Lab Solutions

MI Lab Solutions relates to various products and equipment including culturing media products and trade products involving third party products. Culture media includes a range of culturing media from solid agar plates to liquids in tubes for isolation and identification of microorganisms.

The SSID Group produces, distributes and sells a wide spectrum of different clinical equipment, which is an important pillar in the business in order to a service broader range of products to comply with different customers' demand. The main market for the clinical equipment is microbiological labs, especially located in the Scandinavian countries.

Precision Testing

Precision Testing relates to PCR-products targeted bacteria and fungi. Products in the category include DEC PCR Kit and DEC primer mix used for in vitro diagnostics of diarrhoeagenic E. coli and Dermatophyte PCR Kit used for in vitro diagnostics of dermatophytes in general.

Uncertainty related to recognition and measurement

In the Group's inventory of semifinished goods and raw sera (work in progress), several of the products have an infinite expiration time. The management have decided a valuation principle in which the value only accounts for the goods, which are expected to be consumed within the next five years. The value of semifinished goods and raw sera as of 31 December 2022 is DKKm 29.0 which is at the same level as last year. There is a certain uncertainty associated with the measurement, but it is the management's opinion that the uncertainty has been handled appropriately in the valuation.

Development in the Group's activities and finances

2022 was a year of major changes for SSI Diagnostica Group. The ownership of SSI Diagnostica Group was transferred to a new private equity fund, and the share capital was increased significantly in connection with the large acquisition of TechLab, Inc., Virginia, USA, in August 2022 with a purchase price of 1,930m DKK. The acquisition of TechLab, Inc. contributed positively to the performance of the Group.

The strategy of SSI Diagnostica Group is to achieve a leading global position within the microbiological diagnostic. As part of the strategy the group acquired 100% of the shares in TechLab, Inc., Virginia, USA, in 2022. The acquisition has contributed positively to the planned growth for 2022.

The financial position of the Company and subsidiaries for 2022 is negatively impacted by the decreasing demand for COVID-19 tests and test materials compared to the activity level in the prior two financial years. The lack of COVID-19 sales and test material sales is impacting the segments Rapid Screenings and MI Lab solutions negatively.

Revenue amounts to DKKm 909 for 2022 compared to DKKm 849 in 2021. The increase is a result of the acquisition of TechLab contributing positively to realized revenue but partly offset by the decreasing sales of COVID-19 products.

The result of the activities in 2022 is a profit after tax of DKKm 35 and is below expected net profit of DKKm 100-110 as a result of transactions costs and amortizations related to the acquisition of TechLab. Transaction costs in connection with the acquisition of TechLab, Inc., USA are included with DKKm 34 classified as administration expenses.

Total assets amount to DKKm 3,236 at 31 December 2022 compared to DKKm 930 at 31 December 2021. Total assets are impacted by the acquisition of Techlab, Inc. Total equity amounts to DKKm 1,388 as per 31 December 2022 compared DKKm 505 last year due to a capital contribution of DKKm 1,194 following the acquisition of TechLab, Inc.

During 2022, the activities level in the Group's branch in Sweden targeting marked in Sweden and Norway increased and experienced a growth.

Outlook

The positive impact on sales due to COVID-19 in 2022 is not expected to impact sales for 2023 to the same extent. Sales of non-COVID products are expected to increase, and revenue for 2023 is anticipated to be around DKKm 800-900 and profit before tax for 2023 is anticipated to be around DKKm 0 as a result of increasing goodwill amortisations and interest expenses following the acquisition of TechLab, Inc. in 2022.

Events after the balance sheet date

No events materially affecting the assessment of the Annual Report have occurred after the balance sheet date.

Research and development

The Group has capitalized DKKm 31.9 of the expenses spent on research and development activities related to new products, which are expected to contribute to the future profit. It is the viewpoint of the management that a market exists for these products and it is realistic that the group can penetrate the market. Some of the products were already launched during 2022 while others are still in development.

Foreign branch

The Company has the following foreign branch: SSI Diagnostica A/S, Danmark, Filial i Sverige (branch in Sweden) Herredsvejen 2, 3400 Hillerød, Denmark

Intellectual resources

The most significant intellectual resources consist of the Company's employees. The employees contribute to the Company's earnings in the coming years. Due to growing global organization and market presence, and to strategically harvest the benefits of such growth, the operating model including research and development of SSI Group has been more centralized over the last 2-3 years, with a number of key functions being performed centrally and key strategic and operational activities are centralized at Headquarters.

Financial risks

The Group identifies, monitors, and mitigates financial risks in cooperation with the Company's business units.

With increasing international operating activities, the Group is exposed to foreign currency risks and the risk of exchange fluctuations. The Group handles exchange risks by matching income and expenses in the same currency and by hedging to reduce exposure to exchange rate and interest rates. The Group has entered into agreements in relation to currency swaps and interest rate swaps to reduce the Group's exposure to risks related to currency and interest rate.

Corporate Social Responsibility

Corporate Social Responsibility is an integrated part of the Group's strategy because of the Group's ambition of ensuring a responsible interaction with customers, employees, business partners etc. The Group has implemented global guidelines for "Code of Conduct" which the Group and its stakeholders are committed to follow. The guidelines outline best practice for employees and the

remaining organization and requirements to business partners regarding social, ethical, and environmental issues and anti-corruption and bribery.

The Group's business model is described above in the section "Primary activities".

Environmental affairs

The Group's environmental policy is to permanently reduce the environmental impact of the Company's activities, including to lower consumption of energy on the Group's production, reducing waste volumes as well as to minimize noise from the Group's activities where possible with respect to emissions of particularly CO2. The Group focuses on reusing, rethinking, and recycling of residual products and optimization of energy consumption. In connection with the Group's strategical focus on environmental affairs, operational activities to support the strategy includes establishing action plans to reduce packaging materials and implementing alternative energy sources such as construction of geothermal power sources to reduce emissions of CO2 in connection with new building projects.

The Group has initiated environmental certifications among other things in accordance with ISO 14001 to ensure that the Group's activities meet requirements for environment and sustainability in accordance with international standards.

In 2022, the Group continued mapping of environmental affairs and implemented an Environmental Management System following evaluation of processes, activities and responsibilities. In connection with implementation of Environmental Management System in 2022, the Group evaluated development activities focusing on reducing the Group's environmental impact by, among other things, selecting raw materials etc. based on their environmental impact.

Going forward, the Group will continue to focus on reduction of the Group's environmental impact.

Human Rights and Social Responsibility

The Group is committed to act with a high degree of integrity and ethics and to comply with regulations in the countries where the Group operates. The Group respects UN's Universal Declaration of Human Rights and acknowledges its responsibility to ensure that these rights are complied with in relation to employees.

The Group actively works towards contributing to a safe and healthy work environment and is committed to continuously improve working conditions. The Group supports elimination of all forms of forced labour, child work and discrimination and strives to offer equal opportunity to all human beings regardless of gender, nationality, religion, or ethnic origin. The Group does not accept discrimination or harassment.

The Group has not identified significant risks related to human rights and social responsibility.

To ensure a safe and healthy physical and psychological working conditions for employees, employees receive safety related information and training targeted their specific tasks. Furthermore, the Group conducts employee engagement surveys.

Based on the Group's efforts within Human Rights and Social Responsibility, the Group expects a minimal number of work-related injuries. Furthermore, the Group communicates policies for human

rights to employees to ensure that employees are informed and act in accordance with policies. The Group will continue to have an increased focus on compliance of human rights.

No breaches of policies for human rights and social responsibility were reported during 2022.

Anti-corruption and bribery

The Group is committed to comply with Danish and international legislation on anti-corruption and bribery and prevent corruption and bribery in line with the Code of Conduct. Employees in the Group are introduced to the Code of Conduct to ensure that employees comply with competition legislation etc. The Group has not identified violations of Code of Conduct in 2022 but will continue the work with anti-corruption and bribery. The Group has not identified significant risks related to anti-corruption and bribery.

Diversity

The Group strives to create an organization characterized by diversity and equality among our leaders and employees. The Group has established a Policy for Diversity and Inclusion to ensure equality on all management levels.

The Group is characterized by having a diverse workforce in relation to nationality, gender, age, education etc. and strives to achieve diversity on all levels of the organization.

The Company's Board of Directors currently consists of 7 members, of which 2 women, while our daily management consists of 6 members, of which 3 women.

The Group complies with the definition of an equal composition between genders in accordance with the Danish Business Authority's "Guidance on Target figures, policies and reporting on the gender composition of management" and expects to continue an equal representation of genders going forward.

Statement on Policy for Data Ethics

The Group is committed to ensuring a responsible storage and processing of data in relation to customers, employees and business partners and has initiated an analysis of the Group's treatment of data aiming to formalize a policy for data ethics. The Group has initiated a process of establishing a policy for data ethics, and the policy is expected to be implemented in 2023.

The Group has not previously implemented a Policy for Data Ethics since the Group's primary data collection relates to Personal Data covered by the Group's Privacy Policy.

Financial Highlights

| | | | Group | | |
|---|---|--|---|--|---|
| Amounts in DKK '000 | 2022 | 2021 | 2020 | 2019 | 2018 |
| Income statement | | | | | |
| Revenue Profit/loss from primary activities Net financials Profit/loss for the year | 909.393 82.153 -51.309 35.061 | 849.494 337.433 -31.165 249.561 | 405.224 106.800 -6.447 78.997 | 170.024 31.434 -3.839 20.490 | 162.934 30.579 -6.156 18.934 |
| Balance sheet | | | | | |
| Balance sheet total Investments in property, plant and equipment Equity | 3.236.316 26.491 1.388.084 | 929.708 10.650 504.795 | 926.263 33.721 429.485 | 298.453 3.565 107.836 | 306.010 5.848 97.801 |
| Cash flow | | | | | |
| Operating activities Investing activities Financing activities Cash and cash equivalents | 179.653 -1.989.227 1.884.301 124.770 | 317.150 -5.714 -323.838 52.717 | 90.250 -392.222 441.015 61.967 | 34.031 -9.541 -28.656 -75.635 | 40.871 -9.379 -101.225 -71.469 |
| Ratios | | | | | |
| Revenue growth Gross margin Return on assets Solvency ratio Return on equity | 7% 52% 3% 43% 4% | 110% 62% 36% 54% 53% | 138% 52% 12% 46% 29% | 4% 54% 11% 36% 20% | 192% 49% 11% 26% 27% |

Statement by management on the annual report

The Supervisory and Executive Boards have today discussed and approved the Consolidated Financial Statements and the Parent Company Financial Statements for the financial year 1 January – 31 December 2022 of SSI Diagnostica Holding A/S.

The Financial Statements has been prepared in accordance with the Danish Financial Statements Act.

In our opinion the Consolidated Financial Statements and the Parent Company Financials Statements give a true and fair view of the Group and the Parent Company's financial position at 31 December 2022 and of the result of the Group and the Parent Company's operations for the financial year 1 January – 31 December 2022.

In our opinion the management's review includes a fair review about the matters the review deals with.

We recommend that the Consolidated Financial Statements and the Parent Company's Financial Statements be approved at the annual general meeting.

| Hillerød, 22 May 2023 | | |
|---------------------------------|-----------------------|-----------------------------|
| Executive Board | | |
| Christina Charlotte Lindved | Egil Mølsted Madsen | Søren Skjold Mogensen |
| Supervisory board | | |
| Stig Løkke Pedersen Chairman | Steffen Kjeld Thomsen | Rasmus Karl Gustaf Molander |
| Patrick Olof Dahlén | Catherine Yaping Chen | Sibel Karina Arnes |

Independent auditor's report

To the Shareholders of SSI Diagnostica Holding A/S

Opinion

In our opinion, the Consolidated Financial Statements and the Parent Company Financial Statements give a true and fair view of the financial position of the Group and the Parent Company at 31 December 2022, and of the results of the Group's and the Parent Company's operations as well as the consolidated cash flows for the financial year 1 January - 31 December 2022 in accordance with the Danish Financial Statements Act.

We have audited the Consolidated Financial Statements and the Parent Company Financial Statements of SSI Diagnostica Holding A/S for the financial year 1 January - 31 December 2022, which comprise summary of significant accounting policies, income statement, balance sheet, statement of changes in equity and notes, for both the Group and the Parent Company, as well as consolidated statement of cash flows ("financial statements").

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Group in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Statement on Management's Review

Management is responsible for Management's Review.

Our opinion on the financial statements does not cover Management's Review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read Management's Review and, in doing so, consider whether Management's Review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether Management's Review provides the information required under the Danish Financials Statements Act.

Based on the work we have performed, in our view, Management's Review is in accordance with the Consolidated Financial Statements and the Parent Company Financial Statements and has been

Independent Auditor's Report, continued

prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any material misstatement in Management's Review.

Management's Responsibilities for the Financial Statements

Management is responsible for the preparation of Consolidated Financial Statements and Parent Company Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Group's and the Parent Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Group or the Parent Company or to cease operations, or has no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.

Independent Auditor's Report, continued

- Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Groups and the Parent Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and the Parent Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the Consolidated Financial Statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Hellerup, 22 May 2023

PriewaterhouseCoopers Statsautoriseret Revisionspartnerselskab CVR No 33 77 12 31

Jacob F Christiansen State Authorized Public Accountant mne18628 Søren Alexander State Authorized Public Accountant mne42824

Accounting policies

The Annual Report has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to large enterprises of reporting class C.

The functional currency is Danish kroner, DKK. All other currencies are considered foreign currencies.

Changes in accounting policies

The accounting policies applied remain unchanged from last year except implementation of the following change in presentation of the income statement. Management has decided to change the accounting policies from presentation of the income statement by nature to presentation of the income statement by function. Management evaluates that presentation of the income statement by functions provides a true and fair view of the Company's activities. The comparative figures have been restated.

The change in accounting policy has not affected revenue, profit for the year, assets and equity.

Recognition and measurement

The financial statements have been prepared based on historical cost.

Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised cost are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.

Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.

Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.

On initial recognition, assets and liabilities are measured at cost. Subsequently, assets and liabilities are measured as described below for each financial statement item.

On recognition and measurement, anticipated losses and risks that appear before presentation of the annual report and which confirm or invalidate affairs or conditions existing at the balance sheet date are considered.

Consolidation

The consolidated financial statements include the parent company SSI Diagnostica Holding A/S and companies in which the parent company directly or indirectly holds the majority of the voting rights or in which the parent company, through shareholding or otherwise has a dominant influence. Companies in which the group holds between 20 % and 50 % of the voting rights and exercise significant but non-controlling influence shall be considered as associated companies.

The consolidation shall summarise items of a uniform nature. Intercompany income and costs, shareholdings, dividends and balances, as well as realized and unrealised internal gains and losses on transactions between the consolidated companies are eliminated.

The parent company's shares in the consolidated subsidiaries are offset by the parent company's share of the equity value of the subsidiaries at the time the group relationship was established.

Business combinations

Acquisitions after 1 July 2018

Acquisitions of subsidiaries is treated according to the takeover method, whereby the identifiable assets and liabilities of the acquired entity are measured at fair value at the time of the acquisition. Acquired contingent liabilities are recognised in the consolidated financial statements at fair value to the extent that the value can be reliably measured.

The date of acquisition is the time when the group acquires control of the acquired company.

The purchase price of the acquired business represents the fair value of the agreed remuneration, including remuneration that is contingent on future events. Transaction costs directly attributable to the purchase of subsidiaries are recognised in the profit and loss statement in the consolidated financial statements as they are incurred.

Positive differences between the purchase price of the acquired entity and the identified assets and liabilities are recognised in the balance sheet under intangible fixed assets as goodwill, which is depreciated linearly in the profit and loss statement based at the expected useful life. Goodwill depreciation is allocated in the consolidated financial statements to the functions to which the goodwill relates. If the difference is negative, this is immediately recognised in the profit and loss account.

If the purchase price allocation is not final, positive and negative differences from purchased subsidiaries may, as a result of changes in the recognition and measurement of the identified net assets, be adjusted up to 12 months from the date of acquisition. These adjustments are also reflected in the value of goodwill or negative goodwill, including in depreciations already made.

If the purchase price contains conditional remuneration, these are measured at fair value at the time of acquisition. Subsequently, conditional remuneration at fair value is re-measured. Revaluations are recognised in the income statement.

Acquisitions before 1 July 2018

Acquisitions carried out before 1 July 2018 are treated, with some exceptions, in accordance with accounting policies such as business combinations implemented on or after 1 July 2018. The main exceptions are:

-Identified assets and liabilities of the acquired undertaking shall be recognised only if they are probable.

-Identified contingent liabilities in the acquired company are not recognised in the group balance sheet.

- If the purchase price allocation is not final, positive and negative differences resulting from a change in recognition and measurement of acquired net assets shall be adjusted until the end of the financial year following the year of the acquisition. At the same time, these adjustments are reflected in the value of goodwill or negative goodwill, including in depreciations already made.

- Transaction costs directly attributable to the purchase of subsidiaries are included as part of the cost price.

- Adjustment of conditional remuneration after first recognition is recognised directly by offset on the original purchase price, thereby correcting the value of goodwill or negative goodwill.

Mergers (aggregation method)

The aggregation method is used for business combinations of intercompany companies. The two companies book values are merged and do not identify differences. Any remuneration exceeding the book value of the non surviving company shall be recognised directly at equity. The aggregation method is carried out as if the two companies have always been combined by the adjustment of comparative figures.

Translation policies

Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Exchange differences arising due to differences between the transaction date rates and the rates at the dates of payment are recognised in financial income and expenses in the income statement. Where foreign exchange transactions are considered hedging of future cash flows, the value adjustments are recognised directly in equity.

Receivables, payables and other monetary items in foreign currencies that have not been settled at the balance sheet date is translated at the exchange rates at the balance sheet date. Any differences between the exchange rates at the balance sheet date and the rates at the time when the receivable or the debt arose are recognised in financial income and expenses in the income statement. The profit and loss statement of foreign subsidiaries which are independent entities shall be converted at the rate of the transaction date or at an approximate average rate. The balance sheet items are converted at the exchange rate of the balance sheet date. Exchange rate adjustments arising from the conversion of equity at the beginning of the year and exchange rate adjustments, arising from the conversion of the profit and loss statement at the exchange rate of the balance sheet date, are recognised directly at equity.

Income statement

The income statement has been classified by function.

Revenue

As income recognition criterion, the delivery method is applied so that revenue comprises delivered revenue for the year. Revenue from the sale of manufactured goods and goods for resale is recognized in the income statement when delivery is made and risk has passed to the buyer before the end of the financial year. Revenue is measured at fair value excl. VAT and less granted goods and customer discounts.

Production Costs

Production costs comprises costs incurred to achieve revenue for the year. Cost comprises raw materials, consumables, direct labour costs and indirect production costs such as maintenance and depreciation, etc., as well as operation, administration and management of factories.

Research and development expenses

Research and development expenses comprises research and development costs that do not qualify for capitalisation as well as amortisation of capitalised development costs.

Sales and distribution expenses

Sales and distribution expenses comprises costs in the form of salaries to sales and distribution staff, advertising and marketing expenses.

Administration expenses

Administration expenses comprises expenses related to Management, administrative staff, office expenses, depreciation, etc.

Other operating income and expenses

Other operating income and other operating expenses comprise items of a secondary nature to the main activities of the Group including transaction costs.

Income from investments in group enterprises

Income from investments in group enterprises comprises the pro rata share of the group enterprises' operating profit/loss adjusted for internal profits and losses less annual amortisation of goodwill on consolidation.

Financial income and financial expenses

Financial income and expenses are recognized with amounts regarding the financial year. Financial items comprise interest, costs related to borrowing as well as realised and unrealised exchange gains and losses.

Tax on profit or loss for the year and income taxes

Tax on profit or loss for the year represents 22% of the book profit or loss adjusted for non-taxable and non-deductible items.

Tax on profit or loss for the year consists of the anticipated tax portion of the taxable income for the year adjusted for the changes for the year in deferred tax.

The Company is jointly taxed with other Danish group enterprises. The tax effect of the joint taxation is allocated among the group enterprises in ratio to their taxable income according to the rules on full allocation with a refund for tax losses of the Danish Corporation Tax Act.

Joint tax contributions between the jointly taxed companies which have not been settled at the balance sheet date are classified as liabilities or receivables from joint tax contributions.

The Company is subject to the Danish Tax Prepayment Scheme.

Balance sheet

The balance sheet has been presented in account form.

Assets

Intangible assets

Intangible assets include development projects in progress and completed development projects as well as goodwill.

Intangible assets are measured at cost less accumulated amortisation and impairment losses.

Cost comprises the acquisition price as well as costs directly related to the acquisition until the time when the asset is ready to be put into operation. For own-developed development projects salaries and external costs related to the development are included in the acquisition price.

For own-developed development projects capitalised after 1 January 2016, the carrying amount is transferred from "retained earnings" to "reserve for capitalised development cost" at equity.

Assets are amortised on a straight-line basis over their estimated useful lives:

| Completed development projects | 3-5 years |
|--------------------------------|------------|
| Technology | 20 years |
| Brands | 7- years |
| Customer relations | 7-20 years |
| Goodwill | 5-20 years |

As the intangible assets are not being traded in an active and effective market, no residual values after end of use are included when determining the depreciation period.

The depreciation period for goodwill is determined as an overall assessment of the acquired company´s market position, earnings profile and expectations of customers loyality, which within reasonable limits is based on historical data/registrations.

Property, plant and equipment

Property, plant and equipment are measured at cost less accumulate amortisation and depreciation. The basis of amortisation and depreciation is cost less estimated residual value after the end of useful life. Land is not depreciated.

Cost comprises the acquisition price as well as costs directly related to the acquisition until the time when the asset is ready to be put into operation.

The costprice for an asset is divided into separate components, that are depreciated separately, if the useful life of the individual components is significantly different.

Depreciation is initiated when the assets are ready to be taken into operation. Assets are depreciated on a straight-line basis over their estimated useful lives with following residual values:

ue

| | Useful liv | Residual val |
|------------------------|------------|--------------|
| Buildings | 20 years | 20% |
| Plant and machinery | 3-10 years | 0% |
| Other fixtures, etc. | 3-10 years | 0% |
| Leasehold improvements | 5-7 years | 0% |

Minor purchases with useful lives below one year have been recognized as an expense in the income statement under gross profit.

Profit/loss on sale or scrapping has been included in the income statement under other operating income or other operating expenses.

Leasing

Property, plant and equipment that are assets held under lease and meet the conditions for financial leasing are accounted for according to the same guidelines as owned assets. Assets held under lease are recognized in the balance sheet at the lower of fair value and present value of the future lease payments. On calculation of the present value, the internal interest rate of the lease is applied as discount factor or an approximate value thereof. Assets held under finance lease are depreciated and written down according to the same policies as are determined for the Company's remaining fixed assets.

The capitalised remaining lease commitment is recognized in the balance sheet as a liability other than provisions, and the interest portion of lease payments is recognized over the term of the lease in the income statement.

Impairment of intangible assets and property, plant and equipment

The carrying amount of intangible assets and property plant and equipment is reviewed annually for indication of impairment for loss, apart from what is expressed by usual amortisation and depreciation. If this applies, impairment for loss is made of each asset or group of assets, respectively, to lower recoverable amount.

As recoverable amount, the higher of expected net selling price and net present value is applied. The net present value is calculated as the present value of the anticipated cash flows from the use of the asset or the group of assets.

Impairment for loss for the year is recognized in the income statement as amortisation, depreciation and impairment for loss of property, plant and equipment and intangible assets.

Investments in subsidiaries

Investments in subsidiaries are recognized and measured according to the equity method, so that the investment is measured at the pro rata share of the group enterprises' net asset value adjusted for internal dividends and gains.

Foreign group enterprises' profit or loss and equity have been translated into DKK. Exchange adjustments arising on translation of the foreign group enterprises' and associates' equity at the beginning of the financial year as well as profit/loss for the financial year are recognized at equity.

Distributable reserves in group enterprises and associates which are distributed as dividends to the parent at the balance sheet date are included in the value of investments.

Acquisition of group enterprises and associates are recognized at cost. The difference between the cost price and the net asset value of the acquired company, which appears at the time of establishing the consolidation, is as far as possible allocated to the assets and liabilities whose value is higher or lower than the carrying amount. A remaining positive difference is treated as goodwill and included in the value of investments, which is amortized in the income statement over 5 - 20 years.

The depreciation period is based on an assessment of the market position, earnings profile, and expectations of customers loyalty, which within reasonable limits is based on historical data/registrations. A negative difference, reflecting an expected cost or an unfavourable development, are recognized as income in the income statement in the year of acquisition.

The total net revaluation of investments in group enterprises and associates is allocated via the profit distribution to "reserve for net revaluation according to the equity method" under equity. The reserve is reduced by dividend distributions to the Parent and is adjusted by changes in equity in the group enterprises and associates.

Subsidiaries with negative equity are recognised at DKK 0. Where the parent company has a legal obligation to cover the subsidiary's underbalance, a provision to that effect shall be recognised.

Inventories

Inventories of raw materials and own-produced finished goods are measured at cost according to the FIFO method. In the event of cost exceeding net realisable value, write-down is made to this lower value.

Inventories of goods for resale are measured at cost according to average prices. In the event of cost exceeding net realisable value, write-down is made to this lower value.

Cost of goods for resale as well as raw materials and consumables comprises purchase price.

Cost of own-produced finished goods comprises cost of raw materials, consumables and direct wages plus indirect production costs. Indirect production costs include indirect materials and wages as well as energy costs.

Indirect cost of production includes indirect materials and labour as well as maintenance of and depreciation on the machinery used in production processes, rent for factory buildings and equipment used and cost of production administration and management.

The net realisable value of inventories is calculated at the amount expected to be generated by sale in the process of normal operations with deduction of selling expenses and costs of completion. The net realisable value is determined allowing for marketability, obsolescence and development in expected sales sum.

Receivables

Receivables are measured at amortised cost which usually corresponds to nominal value. The value is reduced by write-down for bad debt according to an individual assessment.

Prepayments

Prepayments comprise costs incurred relating to subsequent financial years including insurance premiums and subscriptions.

Equity and liabilities

Equity

Dividend distribution proposed by Management for the year is disclosed as a separate equity item.

Treasury shares

Cost of acquisition and consideration received are recognised directly in equity as retained earnings.

Provision for deferred tax

Deferred tax is measured according to the liability method. Provision of 22% on all temporary differences between carrying amount and tax-based value of assets and liabilities has been made for deferred tax.

The tax-based values of tax losses carried forward are included in the statement of deferred tax if it is probable that the losses can be utilised.

Current tax receivables and liabilities

Current tax liabilities and receivables are recognised in the balance sheet as the expected taxable income for the year adjusted for tax on taxable incomes for prior years and tax paid on account. Extra payments and repayment under the onaccount taxation scheme are recognised in the income statement in financial income and expenses.

Liabilities other than provisions

Liabilities other than provisions are recognized when raising the loan at the proceeds received after deduction of borrowing costs, direclyt addressed by the loan.

Liabilities other than provisions have been measured at amortised cost which corresponds to nominal value.

Prepayments received from customers

Prepayments received from customers include prepayments from customers.

Cash flow statement

The cash flow statement shows the Company's cash flows for the year as well as the Company's cash and cash equivalents at year-end.

Cash flows from operating activities have been calculated as profit or loss adjusted for non-cash operating items, financial income and expenses paid, corporation taxes as well as increase and decrease in inventories, trade receivables, trade payables and other changes in assets and liabilities other than provisions deriving from operations.

Cash flows from investing activities comprise payments in connection with acquisition and sale of fixed assets.

Cash flows from financing activities comprise payments from inception and repayment of long-term liabilities other than provisions as well as payments made to and received from shareholders.

Cash and cash equivalents comprise cash funds as well as operating credits at credit institutions included in the Company's cash management.

Financial highlights

The ratios have been prepared in accordance with "Guidelines and ratios 2015 " from The Danish Finance Analysts Society. The ratios have been calculated as follows:

 $Return on assets = \frac{Operating \ profit \times 100}{Average \ invested \ capital}$

 $Solvency \ ratio = \frac{Equity \ at \ closing \ balance \times 100}{Total \ assets}$

 $Return on \ equity = \frac{Profit \ or \ loss \ for \ the \ year \times 100}{Average \ equity}$

Invested capital = Intangible and fixed assets relating to the activities + networking capital

Income statement 1 January – 31 December 2022

| | | Group | Group | Parent | Parent |
|------|--|--------------|--------------|------------|-------------|
| Note | | 2022 | 2021 | 2022 | 2021 |
| | | DKK | DKK | DKK | DKK |
| 1 | Revenue | 909.392.705 | 849.493.997 | 2.068.500 | 2.068.500 |
| 2 | Production costs | -439.576.125 | -320.746.394 | 0 | 0 |
| | Gross profit | 469.816.580 | 528.747.603 | 2.068.500 | 2.068.500 |
| 2 | Research and development expenses | -31.756.419 | -42.762.951 | 0 | 0 |
| 2 | Sales and distribution expenses | -73.220.638 | -45.455.777 | 0 | 0 |
| 2 | Administration expenses | -289.665.235 | -103.095.763 | -6.916.767 | -5.404.223 |
| | Operating expenses | -394.642.291 | -191.314.492 | -6.916.767 | -5.404.223 |
| | Other operating income | 6.978.617 | 0 | 764.200 | 0 |
| | Operating profit/loss | 82.152.906 | 337.433.111 | -4.084.067 | -3.335.723 |
| | Income from investments in group enterprises | 0 | 0 | 33.951.122 | 255.769.390 |
| 3 | Financial income | 96.898.162 | 7.679.799 | 8.075.438 | 0 |
| 4 | Financial expenses | -148.206.830 | -38.844.987 | -1.137.446 | -4.768.982 |
| | Profit/loss before tax | 30.844.238 | 306.267.923 | 36.805.047 | 247.664.685 |
| 5 | Tax on profit/loss for the year | 4.216.813 | -56.707.303 | -1.743.996 | 1.895.935 |
| | Profit/loss for the year | 35.061.051 | 249.560.620 | 35.061.051 | 249.560.620 |

Balance sheet at 31 December 2022

| Assets | | Group | Group | Parent | Parent |
|--------|-------------------------------------|---------------|-------------|---------------|-------------|
| Notes | | 31/12 2022 | 31/12 2021 | 31/12 2022 | 31/12 2021 |
| | | DKK | DKK | DKK | DKK |
| 7 | Completed development projects | 8.198.872 | 13.716.359 | 0 | 0 |
| 7 | Technology | 169.662.600 | 0 | | |
| 7 | Brand | 265.785.060 | 37.642.494 | 0 | 0 |
| 7 | Customer relations | 632.617.932 | 119.455.572 | 0 | 0 |
| 7 | Goodwill | 1.542.566.061 | 401.427.233 | 0 | 0 |
| 7 | Development projects in progress | 38.442.488 | 6.541.281 | 0 | 0 |
| | Intangible assets | 2.657.273.013 | 578.782.938 | 0_ | 0 |
| 8 | Land and buildings | 78.115.579 | 25.650.716 | 0 | 0 |
| 8 | Plant and machinery | 20.376.462 | 9.666.416 | 0 | 0 |
| 8 | Other fixtures etc. | 14.669.586 | 31.334.263 | 0 | 0 |
| 8 | Leasehold improvements | 15.409.484 | 7.200.612 | 0 | 0 |
| 8 | Prepayments, fixed assets | 978.260 | 592.201 | 0 | 0 |
| | Property, plant and equipment | 129.549.371 | 74.444.209 | 0 | 0 |
| 9 | Investments in group enterprises | 0 | 0 | 1.023.338.598 | 701.378.950 |
| 10 | Deposits | 257.891 | 263.929 | 0 | 0 |
| | Other investments | 0 | 0 | 0 | 0 |
| 16 | Other receivables | 28.771.010 | 0 | 0 | 0 |
| | Fixed asset investments | 29.028.901 | 263.929 | 1.023.338.598 | 701.378.950 |
| | Fixed assets | 2.815.851.285 | 653.491.076 | 1.023.338.598 | 701.378.950 |
| | Raw materials and consumables | 60.457.261 | 41.627.320 | 0 | 0 |
| 11 | Work in progress | 29.746.504 | 33.062.646 | 0 | 0 |
| | Finished goods and goods for resale | 63.455.572 | 43.290.420 | 0 | 0 |
| | Prepayments of goods | 4.472.316 | 13.671.896 | 0 | 0 |
| | Inventories | 158.131.652 | 131.652.281 | 0 | 0 |

Balance sheet at 31 December 2022

| Assets | | Group | Group | Parent | Parent |
|--------|------------------------------------|---------------|-------------|---------------|-------------|
| Notes | | 31/12 2022 | 31/12 2021 | 31/12 2022 | 31/12 2021 |
| | | DKK | DKK | DKK | DKK |
| | Trade receivables | 105.027.910 | 73.487.238 | 0 | 0 |
| | Joint tax contribution receivables | 23.005.818 | 11.362.914 | 0 | 1.895.935 |
| | Other receivables | 200.519 | 2.628.608 | 0 | 0 |
| | Receivables from group enterprises | 0 | 0 | 365.688.777 | 0 |
| | Deferred tax assets | 1.313.232 | 594.922 | 0 | 0 |
| 12 | Prepayments | 8.015.589 | 3.774.011 | 28.275 | 13.000 |
| | Receivables | 137.563.069 | 91.847.693 | 365.717.052 | 1.908.935 |
| | Cash and cash equivalents | 124.769.523 | 52.716.594 | 331.436 | 0 |
| | Current assets | 420.464.244 | 276.216.568 | 366.048.488 | 1.908.935 |
| | Total assets | 3.236.315.529 | 929.707.645 | 1.389.387.086 | 703.287.885 |

Balance sheet at 31 December 2022

| Equity and | d liabilities | Group | Group | Parent | Parent |
|------------|--|---------------|-------------|---------------|-------------|
| Notes | | 31/12 2022 | 31/12 2021 | 31/12 2022 | 31/12 2021 |
| | | DKK | DKK | DKK | DKK |
| 13 | Share capital Reserve for net revaluation according to the | 11.058.400 | 7.180.600 | 11.058.400 | 7.180.600 |
| | equity method | 0 | 0 | 0 | 207.845.193 |
| | Foreign currency translation adjustments | -9.973.432 | 35.314.976 | 20.685.184 | 0 |
| | Retained earnings | 1.386.999.033 | 462.299.207 | 1.356.340.417 | 289.768.990 |
| | Equity | 1.388.084.000 | 504.794.783 | 1.388.084.000 | 504.794.783 |
| | Provision for deferred tax | 266.735.479 | 68.344.897 | 0 | 0 |
| | Total provisions | 266.735.479 | 68.344.897 | 0 | 0 |
| | | | | | |
| 15 | Debt to credit institutions | 1.392.550.870 | 203.418.000 | 0 | 105.000.000 |
| 15 | Other payables (long-term part) | 5.290.264 | 5.050.165 | 0 | 0 |
| | Long-term liabilities other than provisions | 1.397.841.134 | 208.468.165 | 0 | 105.000.000 |
| | | | | | |
| 15 | Current portion of long-term liabilities other than provisions | 88.887.554 | 35.000.000 | 0 | 35.000.000 |
| | Other credit institutions | 0 | 9.461.804 | 0 | 9.461.804 |
| | Prepayments received from customers | 4.832.759 | 12.590.985 | 0 | 0 |
| | Trade payables | 35.668.826 | 48.324.090 | 0 | 0 |
| | Payables to group enterprises Income tax | 0 | 0 | 0 | 48.177.073 |
| | payables | 4.193.843 | 17.142 | 1.015.910 | 0 |
| | Other payables | 50.071.935 | 42.705.778 | 287.175 | 854.225 |
| | Short-term liabilities other than provisions | 183.654.916 | 148.099.799 | 1.303.085 | 93.493.102 |
| | Liabilities other than provisions | 1.581.496.050 | 356.567.964 | 1.303.085 | 198.493.102 |
| | Total equity and liabilities | 3.236.315.529 | 929.707.645 | 1.389.387.086 | 703.287.885 |
| 6 | Distribution of profit/loss | | | | |
| 14 | Treasury shares | | | | |

- 14 Treasury shares
- 19 Contingent liabilities
- 20 Contractual obligations
- 21 Related parties
- 22 Audit fees to auditors appointed at the Annual General Meeting

Statement of change in equity 31 December 2022

| | | | Group | |
|--|------------|---------------|------------------|---------------|
| | Share | Retained | Foreign currency | |
| | capital | earnings | adjustment | Total |
| | DKK | DKK | DKK | DKK |
| Equity at 1/1 2022 | 7.180.600 | 462.299.207 | 35.314.976 | 504.794.783 |
| Capital increase | 3.877.800 | 1.189.638.774 | 0 | 1.193.516.574 |
| Net profit/loss for the year | 0 | 35.061.051 | 0 | 35.061.051 |
| Extraordinary dividend | 0 | -300.000.000 | 0 | -300.000.000 |
| Foreign currency translation adjustments | 0 | 0 | -45.288.408 | -45.288.408 |
| Equity at 31/12 2022 | 11.058.400 | 1.386.999.033 | -9.973.432 | 1.388.084.000 |

Parent

| | | Net revaluation | | | |
|--|------------|-----------------|---------------|------------------|---------------|
| | Share | acc. to | Retained | Foreign currency | |
| | capital | equity method | earnings | adjustment | Total |
| | DKK | DKK | DKK | DKK | DKK |
| Equity at 1/1 2022 | 7.180.600 | 207.845.193 | 289.768.990 | 0 | 504.794.783 |
| Capital increase | 3.877.800 | 0 | 1.189.638.774 | 0 | 1.193.516.574 |
| Net profit/loss for the year | 0 | -141.871.601 | 176.932.652 | 0 | 35.061.051 |
| Extraordinary dividend | 0 | 0 | -300.000.000 | 0 | -300.000.000 |
| Foreign currency translation adjustments | 0 | -65.973.592 | 0 | 20.685.184 | -45.288.408 |
| Equity at 31/12 2022 | 11.058.400 | 0 | 1.356.340.417 | 20.685.184 | 1.388.084.000 |

Cash flow statement 1 January – 31 December 2022

| | | Group | Group |
|------|---|----------------|--------------|
| Note | | 2022 | 2021 |
| | | DKK | DKK |
| | Profit/loss for the year | 35.061.051 | 249.560.620 |
| 17 | Adjustments | 203.118.390 | 151.753.600 |
| 18 | Changes in net working capital | 2.773.320 | 1.346.254 |
| | Interest received | 2.612.695 | 5.268.858 |
| | Interest paid | -39.397.628 | -19.830.370 |
| | Cash from operating profit/loss | 204.167.828 | 388.098.962 |
| | Income tax paid/refund | -24.514.451 | -70.949.219 |
| | Cash flows from operating activities | 179.653.377 | 317.149.743 |
| | Development projects | -31.885.378 | -4.144.656 |
| | Acquisition of property, plant and equipment (reduced by prepayments) | -25.833.748 | -18.741.755 |
| | Acquisition of intangible assets | -531.440 | 0 |
| | Acquisition of business combinations | -1.929.871.866 | 0 |
| | Sale of property, plant and equipment | 0 | 9.603 |
| | Adjustments of acquisition of business combination | -1.104.997 | 17.162.564 |
| | Cash flows from investing activities | -1.989.227.428 | -5.714.244 |
| | Payment of debt to credit institutions | -475.539.920 | -115.300.000 |
| | Acquisition of treasury shares | 0 | -218.000.000 |
| | Inception of debt from credit institutions | 1.500.000.000 | 0 |
| | Acquired loan costs | -15.500.000 | 0 |
| | Credit facilities at credit institutions | 0 | 9.461.804 |
| | Paid dividends | -300.000.000 | 0 |
| | Cash contributed share capital | 1.175.340.764 | 0 |
| | Cash flows from financing activities | 1.884.300.845 | -323.838.196 |
| | Changes in cash and cash equivalents during the year | 74.726.793 | -12.402.697 |
| | Cash and cash equivalents at 1/1 2022 | 52.716.594 | 61.966.836 |
| | Cash and cash equivalents at 31/12 2022 | 127.443.387 | 49.564.139 |
| | Exchange rate adjustments of cash | -2.673.864 | 3.152.455 |
| | | 124.769.523 | 52.716.594 |
| | Cash | | |
| | Cash and cash equivalents at 31/12 2022 | 124.769.523 | 52.716.594 |
| | Unused credit facilities at 31/12 2022 | 299.769.523 | 83.254.790 |

| | | Group | Group | Parent | Parent |
|---|-----------------------|--------------------|--------------------|--------------------|--------------------|
| 1 | Revenue | <u>2022</u> DKK | <u>2021</u> DKK | <u>2022</u> DKK | <u>2021</u> ДКК |
| | Disease Prevention | 75.766.750 | 75.079.329 | 0 | 0 |
| | Rapid screenings | 612.904.995 | 432.664.440 | 0 | 0 |
| | MI Lab Solutions | 158.714.025 | 288.977.018 | 0 | 0 |
| | Precision Testing | 17.566.713 | 18.757.718 | 0 | 0 |
| | Other | 44.440.221 | 34.015.491 | 2.068.500 | 2.068.500 |
| | Total revenue | 909.392.705 | 849.493.997 | 2.068.500 | 2.068.500 |
| | Geographical Segments | | | | |
| | Denmark | 316.032.588 | 401.187.083 | 2.068.500 | 2.068.500 |
| | Rest of the World | 593.360.118 | 448.306.914 | 0 | 0 |
| | Total revenue | 909.392.705 | 849.493.997 | 2.068.500 | 2.068.500 |

| | | Group | Group | Parent | Parent |
|---|--|-------------|-------------|-----------|-----------|
| 2 | Staff costs | 2022 | 2021 | 2022 | 2021 |
| | | DKK | DKK | DKK | DKK |
| | Salary and wages | 179.311.570 | 104.554.517 | 3.229.342 | 3.130.376 |
| | Change in holiday allowance | 4.544.507 | 808.080 | 20.472 | 19.510 |
| | Pensions | 15.215.342 | 4.194.838 | 734.997 | 631.520 |
| | Other social security costs | 23.996.636 | 28.129.301 | 12.717 | 0 |
| | Refunds | -1.287.463 | -622.474 | 0 | 0 |
| | Other staff costs | 6.669.069 | 6.491.423 | 0 | 0 |
| | Total | 228.449.660 | 143.555.685 | 3.997.528 | 3.781.406 |
| | Wages and Salaries, pensions and other social security expenses are recognised in the following cost function: | | | | |
| | Cost of production | 98.814.284 | 66.889.240 | 0 | 0 |
| | Research and development costs | 34.912.018 | 25.185.994 | 0 | 0 |
| | Sales and distribution costs | 50.513.532 | 29.834.497 | 0 | 0 |
| | Administration costs | 44.209.829 | 21.645.955 | 3.997.528 | 3.781.406 |
| | Total employee costs | 228.449.663 | 143.555.685 | 3.997.528 | 3.781.406 |
| | The average number of full-time employees has represented | 666 | 477 | 2 | 2 |

The total remuneration of the Executive Board and the Supervisory Board amounts to DKKk 2,506 in the financial year against DKKk 2,506 last year.

The Parent Company has issued 1.810 warrants to Executive Management and Senior Executives. Warrants are vested over the period 2020-2027 with 20% per year. All warrants can, regardless of the vesting period, be exercised by the holders in a future exit from the Company. Each warrant entitles the holder to subscribe for one share with a nominal value of DKK 100 and an exercise price of DKK 12,340 and 30,911.

| | | Group | Group | Parent | Parent |
|---|---|-------------|------------|-----------|------------|
| 3 | Financial income | 2022 | 2021 | 2022 | 2021 |
| | | DKK | DKK | DKK | DKK |
| | Interest income from group companies | 0 | 0 | 8.075.438 | 0 |
| | Other financial income | 115.251 | 1.996 | 0 | 0 |
| | Interest income, currency swaps | 2.497.444 | 0 | 0 | 0 |
| | Fair value adjustment, SWAPS | 28.771.010 | 0 | 0 | 0 |
| | Unrealised gains on foreign exchange | 65.514.458 | 7.677.803 | 0 | 0 |
| | Total | 96.898.162 | 7.679.799 | 8.075.438 | 0 |
| | | Group | Group | Parent | Parent |
| 4 | Financial expenses | 2022 | 2021 | 2022 | 2021 |
| | | DKK | DKK | DKK | DKK |
| | Interest expenses to group companies | 0 | 0 | 0 | 697.239 |
| | Interest expenses, credit institutions | 37.685.453 | 0 | 1.107.827 | 0 |
| | Other financial expenses | 1.536.708 | 9.496.121 | 29.619 | 4.071.743 |
| | Unrealised loss on foreign exchange | 108.984.669 | 29.348.866 | 0 | 0 |
| | Total | 148.206.830 | 38.844.987 | 1.137.446 | 4.768.982 |
| | | Group | Group | Parent | Parent |
| | Tax on profit/loss for the year, corporation tax and deferred | | | | |
| 5 | tax | 2022 | 2021 | 2022 | 2021 |
| | | DKK | DKK | DKK | DKK |
| | Tax on profit/loss for the year: | | | | |
| | Tax on taxable income for the year | 28.044.048 | 65.920.911 | 1.015.910 | -1.895.935 |
| | Tax on taxable income previously year | 0 | 0 | 728.086 | 0 |
| | Deferred tax | -32.260.861 | -9.213.608 | 0 | 0 |
| | Total | -4.216.813 | 56.707.303 | 1.743.996 | -1.895.935 |

| | | Group | Group | Parent | Parent |
|---|-----------------------------|------------|-------------|------------|-------------|
| 6 | Distribution of profit/loss | 2022 | 2021 | 2022 | 2021 |
| | | DKK | DKK | DKK | DKK |
| | | | | | |
| | Retained earnings | 35.061.051 | 249.560.620 | 35.061.051 | 249.560.620 |
| | Profit/loss for the year | 35.061.051 | 249.560.620 | 35.061.051 | 249.560.620 |

7 Intangible assets

Group

| | Completed | | | | | Development | |
|---|-------------------------|-------------|-------------|-----------------------|---------------|-------------------------|-------------------------------|
| | development projects | Technology | Brands | Customer relations | Goodwill | projects in progress | Intangible assets in total |
| | DKK | DKK | DKK | DKK | DKK | DKK | DKK |
| Cost at 1/1 2022 | 23.213.036 | 0 | 46.160.138 | 146.485.665 | 467.690.364 | 6.541.281 | 690.090.483 |
| Additions for the year Acquisition of business | 0 | 0 | 531.440 | 0 | 1.104.997 | 31.885.378 | 33.521.814 |
| combinations | 0 | 181.251.950 | 248.684.617 | 563.977.992 | 1.229.348.322 | 0 | 2.223.262.881 |
| Transfers for the year | 132.357 | 0 | 0 | 0 | 0 | -132.357 | 0 |
| Exchange rate adjustments | 586.118 | -8.347.390 | -8.561.423 | -16.797.477 | -42.493.867 | 148.186 | -75.465.853 |
| Cost at 31/12 2022 | 23.931.511 | 172.904.560 | 286.814.772 | 693.666.180 | 1.655.649.816 | 38.442.488 | 2.871.409.326 |
| Amortization at 1/1 2022 | 9.496.677 | 0 | 8.517.645 | 27.030.090 | 66.263.131 | 0 | 111.307.543 |
| Amortization for the year | 6.036.285 | 3.266.166 | 12.127.008 | 32.753.734 | 46.288.151 | 0 | 100.471.344 |
| Exchange rate adjustments | 199.678 | -24.207 | 385.059 | 1.264.424 | 532.472 | 0 | 2.357.426 |
| Amortization at 31/12 2022 | 15.732.639 | 3.241.959 | 21.029.712 | 61.048.248 | 113.083.755 | 0 | 214.136.313 |
| Carrying amount at 31/12 2022 | 8.198.872 | 169.662.600 | 265.785.060 | 632.617.932 | 1.542.566.061 | 38.442.488 | 2.657.273.013 |

8 Property, plant and equipment

Group

| | | | | | Prepayments |
|--------------------------------------|------------|------------|-------------------|-------------|-----------------|
| | Land and | Plant and | Other fixtures | Leasehold | property, plant |
| | buildings | machinery | and fittings ect. | improvement | and equipment |
| | DKK | DKK | DKK | DKK | DKK |
| Cost at 1/1 2022 | 26.760.754 | 30.045.386 | 40.611.893 | 10.861.855 | 592.201 |
| Additions for the year | 18.368.457 | 3.571.993 | 4.228.933 | 321.970 | 978.260 |
| Disposals for the year | 0 | -336.341 | -91.524 | -48.439 | 0 |
| Acquisition of business combinations | 35.641.326 | 4.696.796 | 1.517.358 | 2.311.942 | 0 |
| Transfers for the year | 1.083.181 | 11.802.037 | -23.895.666 | 17.381.058 | -592.201 |
| Exchange rate adjustments | -1.641.893 | -271.817 | -135.905 | 192.087 | 0 |
| Cost at 31/12 2022 | 80.211.825 | 49.508.053 | 22.235.090 | 31.020.472 | 978.260 |
| | | | | | |
| Depreciation at 1/1 2022 | 1.110.038 | 20.378.970 | 9.277.630 | 3.661.243 | 0 |
| Depreciation for the year | 752.131 | 5.204.928 | 2.742.020 | 5.105.508 | 0 |
| Depreciation, disposals for the year | -54.607 | -109.057 | -30.635 | -19.403 | 0 |
| Transfers for the year | 308.707 | 3.692.406 | -4.429.232 | 6.798.737 | 0 |
| Exchange rate adjustments | -20.023 | -35.656 | 5.721 | 64.903 | 0 |
| Depreciation at 31/12 2022 | 2.096.246 | 29.131.591 | 7.565.504 | 15.610.988 | 0 |
| | | | | | |
| Carrying amount at 31/12 2022 | 78.115.579 | 20.376.462 | 14.669.586 | 15.409.484 | 978.260 |

| | | Pare | nt |
|---|---|---------------|-------------|
| 9 | Investments in group enterprises | 2022 | 2021 |
| | | DKK | DKK |
| | | | |
| | Cost at 1/1 2022 | 487.007.596 | 487.007.596 |
| | Additions for the year | 0 | 0 |
| | Contribution to subsidiary | 833.296.933 | 0 |
| | Cost at 31/12 2022 | 1.320.304.529 | 487.007.596 |
| | | | |
| | Revaluation at 1/1 2022 | 411.020.458 | 154.787.446 |
| | Revaluation for the year | 34.414.745 | 256.233.012 |
| | Revaluation at 31/12 2022 | 445.435.203 | 411.020.458 |
| | | | |
| | Amortizations and impairment at 1/1 2022 | 203.139.819 | 246.888.905 |
| | Received dividends in the financial year | 500.000.000 | 0 |
| | Exchange rate adjustments | 45.288.408 | -43.749.086 |
| | Amortization, depreciation and impairment at 31/12 2022 | 748.428.227 | 203.139.819 |
| | | | |
| | Carrying amount at 31/12 2022 | 1.017.311.505 | 694.888.235 |
| | | | |
| | Equity according to Financial Statements | 1.017.311.505 | 694.888.235 |
| | Goodwill on consolidation | 9.272.447 | 9.272.447 |
| | Accumulated amortizations | -3.245.354 | -2.781.732 |
| | Carrying amount at 31/12 2022 | 1.023.338.598 | 701.378.950 |
| | | | |

9 Investments in group enterprises, continued

| Group ente | erprises | Hometown | Share capital | Ownership | Equity | Profit or loss |
|--------------------|------------------------|-----------------|---------------|------------|---------------|----------------|
| | | | DKK | percentage | DKK | DKK |
| SSI Diagnos | stica A/S | Hillerød, DK | 1.764.200 | 100% | 1.016.146.351 | 38.062.225 |
| SSI Diagnos | stica USA LLC | California, US | 0 | 100% | 955.283.342 | -55.628.282 |
| SSI Consult | ing (Hangzhou) Co. Ltd | Hangzhou, China | 75.620.124 | 100% | 111.865.478 | 390.648 |
| SSI Diagnos | stica A/S, DK, Filial | Malmö, Sweden | 0 | 100% | 291.911 | 89.471 |
| Reagensia / | AB | Malmö, Sweden | 0 | 100% | 0 | 0 |
| CTK Biotecl | h, Inc. | California, US | 63.627 | 100% | 57.268.190 | 50.062.625 |
| Beijing Gen | nesee Biotech, Inc. | Beijing, China | 1.407.750 | 100% | 35.895.503 | 107.329.523 |
| Techlab, In | с | Virginia, US | 51.734 | 100% | 235.129.177 | 28.379.814 |
| | | | | | | |
| 10 Deposits | | | | | 2022 | 2021 |
| | | | | | DKK | DKK |
| Cost at 1/ | 1 2022 | | | | 263.929 | 263.929 |
| Additions | for the year | | | | 46.034 | 0 |
| • | for the year | | | | -52.072 | 0 |
| Cost at 31 2022 | ./12 | | | | 257.891 | 263.929 |
| Carrying a | amount at 31/12 | | | | | |
| 2022 | | | | | 257.891 | 263.929 |

11 Work in progress

In the company's inventory of semifinished goods and raw sera (work in progress), several of the products have an infinite expiration time. The management have decided a valuation principle in which the value only accounts for the goods, which are expected to be consumed within the next five years. The value of semifinished goods and raw sera as of 31 December 2021 is DKKm 29.0. There is a certain uncertainty associated with the measurement, but it is the management's opinion, that the uncertainty has been handled appropriately in the valuation.

| | | Group | Group | Parent | Parent |
|----|------------------------------------|---------------|---------------|------------|---------------|
| 12 | Prepayments (receivables) | 31/12 2022 | 31/12 2021 | 31/12 2022 | 31/12 2021 |
| | | DKK | DKK | DKK | DKK |
| | Insurance, subscription fees, etc. | 8.015.589 | 3.774.011 | 28.275 | 13.000 |
| | Total | 8.015.589 | 3.774.011 | 28.275 | 13.000 |

13 Share capital

The share capital consists of 11,058 certificates of DKK 100.

The shares consist of only one share class and include no special rights, preferences or restrictions. All shares are fully paid up

14 Treasury shares

2022

The company owns no treasury shares at 31 December 2022.

2021

The company purchased own issued B shares of DKK 5,000,000 at a total price of DKK 218,000,000 in 2021 following a payment of former shareholder. The company's share capital was in 2021 reduced by DKK 5,000,000 treasury B-shares by annulment of the shares.

The company owned no treasury shares at 31 December 2021.

15 Long-term liabilities other than provisions

| 5 | Long-term liabilities other than provisions | Group | Parent |
|---|---|---------------|---------|
| | | 2022 | 2022 |
| | Credit institutions: | DKK | DKK |
| | Instalments next financial year | 88.887.554 | 0 |
| | Debt outstanding between 1 and 5 years | 311.112.446 | 0 |
| | Debt outstanding after 5 years | 1.081.438.424 | 0 |
| | | | |
| | Total debt | 1.481.438.424 | 0 |
| | | | |
| | Other payables: | | |
| | Instalments next financial year | 50.071.935 | 0 |
| | Debt outstanding between 1 and 5 years | 5.290.264 | 287.174 |
| | Debt outstanding after 5 years | 0 | 0 |
| | | | |
| | Total debt | 55.362.199 | 287.174 |
| | | | |

Parent

16 Derivative financial instruments

The Group has entered into agreements in relation to hedging of interest rate risks and exchange rate risks.

The fair value of derivative financial instruments at 31 December 2022 is DKKm 28.8 (2021: DKKm 0) recognised as Other Receivables. The fair value movement on the hedging instruments are recognised in the income statement. The maturity date of the hedging instruments is 30 September 2025.

17 Cash flow - adjustments

| .7 | Cash flow - adjustments | Group | |
|----|---|-------------|-------------|
| | | 2022 | 2021 |
| | | DKK | DKK |
| | Amortisation, depreciation and impairment for | | |
| | loss of intagible and tangible fixed assets | 156.026.535 | 63.881.109 |
| | Financial income | -96.898.162 | -7.679.799 |
| | Financial costs | 148.206.830 | 38.844.987 |
| | Tax on profit/loss for the year | -4.216.813 | 56.707.303 |
| | | 203.118.390 | 151.753.600 |
| | | | |

18 Cash flow - changes in working capital items

| o o i | | • |
|--|-------------|-------------|
| | 2022 | 2021 |
| | DKK | DKK |
| Change in inventories | 23.278.265 | -12.416.706 |
| Change in trade receivables | 13.167.811 | -17.146.426 |
| Changes in other receivables | 2.428.089 | 17.213.716 |
| Changes in prepayments | -54.675 | -1.823.546 |
| Change in trade payables | -17.590.147 | 17.952.027 |
| Prepayment from customers | -7.758.226 | 4.611.384 |
| Changes in other payables | -11.802.793 | 10.118.368 |
| Of which relating to investment activities | 1.104.997 | -17.162.564 |
| | 2.773.320 | 1.346.254 |
| | | |

19 Contingent liabilities

Parent company

The company has submitted an absolute guarantee against SSI Diagnostica A/S' liabilities to credit institutions. In addition, the company has pawned its shares in SSI Diagnostica A/S as security for the company's and SSI Diagnostica A/S's liabilities to credit institutions.

The company is jointly taxed with other group companies and is jointly liable with the other group companies for payable and unsettled corporation and withholding taxes. The total amount for payable corporate tax is shown in the annual report for Adelis Services 1 ApS. Any subsequent corrections to the corporate tax and witholding taxes can lead to a higher liability for the Company.

Group

20 Contractual obligations

The Group

The Group has entered into lease agreements which are interminable until respectively 2023, 2024, 2025 and 2030. The total lease liability until termination is possible amounts to DKKm 50. The annual rent excl. operation costs and consumption costs amounts in 2022 to DKKm 17.

The Group has provided a guarantee against landlord as security for any debt between landlord and tenant. The guarantee amounts to DKKm 0.9.

21 Related parties

The Company's related parties comprise the following:

Group Companies

SSI Diagnostica USA LLC, California US SSI Consulting (Hangzhou) Co. Ltd, Hangzhou, China CTK Biotech, Inc., California US Beijing Genesee Biotech, Inc., Beijing China Techlab, Inc., Virginia

Main shareholder (controlling influence)

SSID Invest AB Biblioteksgatan 11, 111 46 Stockholm

In accordance with section 98(c)(7) of the Danish Financial Statements Act, no transactions with related parties have been disclosed as Management believes that all transactions with related parties have been carried out on arm's length basis.

| 22 | Audit fees to auditors appointed at the Annual General Meeting | Group | Group | Parent | Parent |
|----|--|---------------|---------------|---------------|---------------|
| | | 31/12 2022 | 31/12 2021 | 31/12 2022 | 31/12 2021 |
| | PricewaterhouseCoopers | DKK | DKK | DKK | DKK |
| | Audit fee | 643.985 | 801.242 | 0 | 108.747 |
| | Tax advisory services | 2.431.380 | 1.367.059 | 423.519 | 505.244 |
| | Non-audit services | 200.000 | 330.110 | 116.450 | 0 |
| | Total | 3.275.365 | 2.498.411 | 539.969 | 613.991 |
| | | | | | |
| | Other audit companies | | | | |
| | Audit fee | 331.435 | 601.527 | 0 | 0 |
| | Tax advisory services | 117.612 | 145.221 | 0 | 0 |
| | Non-audit services | 2.446.368 | 433.642 | 0 | 0 |
| | Total | 2.895.415 | 1.180.390 | 0 | 0 |